UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): | June 28, 2006 |
Neose Technologies, Inc.
__________________________________________
(Exact name of registrant as specified in its charter)
Delaware | 000-27718 | 13-3549286 |
_____________________ (State or other jurisdiction |
_____________ (Commission |
______________ (I.R.S. Employer |
of incorporation) | File Number) | Identification No.) |
102 Witmer Road, Horsham, Pennsylvania | 19044 | |
_________________________________ (Address of principal executive offices) |
___________ (Zip Code) |
Registrants telephone number, including area code: | 215-315-9000 |
Not Applicable
______________________________________________
Former name or former address, if changed since last report
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01 Other Events.
Neose Technologies, Inc. today identified Factors VIIa, VIII and IX as the three proteins that are the subject of license agreements it entered into with Novo Nordisk A/S in November 2003.
Item 9.01 Financial Statements and Exhibits.
The attached exhibit index is hereby incorporated by reference.
Neose “Safe Harbor” Statement under the Private Securities Litigation Reform Act of 1995: Statements in this Form 8-K regarding our business that are not historical facts are “forward-looking statements” that involve risks and uncertainties, including the risk that the collaboration will not continue or will not be successful, or that long-acting versions of Factors VIIa, VIII and IX will not be successfully developed. For a discussion of these risks and uncertainties, any of which could cause our actual results to differ from those contained in the forward-looking statement, see the section of Neose’s Annual Report on Form 10-K for the year ended December 31, 2005, entitled “Factors Affecting the Company’s Prospects” and discussions of potential risks and uncertainties in Neose’s subsequent filings with the SEC.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Neose Technologies, Inc. | ||||
June 28, 2006 | By: |
A. Brian Davis
|
||
|
||||
Name: A. Brian Davis | ||||
Title: Senior Vice President and CFO |
Exhibit Index
Exhibit No. | Description | |
|
|
|
99.1
|
Press release dated June 28, 2006. |